Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

VITAL trial: Safety of vosaroxin and infusional cytarabine for frontline treatment of AML

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 27.01.20
Views: 314

Dr Stephen Strickland - Vanderbilt University Medical Center, Nashville, USA

Dr Stephen Strickland speaks to ecancer at the ASH 2019 meeting in Orlando about the VITAL trial of vosaroxin and infusional cytarabine for the frontline treatment of acute myeloid leukaemia (AML).

He explains that the trial focused on a high-risk patient population, including patients who were over 6555years of age or who were 18-54 with high-risk features.

Dr Strickland reports that the combination was reasonably safe and well-tolerated in this patient population. He suggests that it has the potential to replace anthracyclin based induction in the first setting.

Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation